Advanced non–small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations markedly respond to EGFR tyrosine kinase inhibitors (TKIs) [1-3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.